An observational study in Malignant Colorectal Polyp, Colorectal Cancer and T1 Colorectal Cancer, sponsored by Memorial Sloan Kettering Cancer Center. Recruiting at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Memorial Sloan Kettering Cancer Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies in Colorectal Neoplasms by Memorial Sloan Kettering Cancer Center — 12 open to participants now, 18 under way, none of them phase 3. Colorectal Neoplasms · Memorial Sloan Kettering Cancer Center.
Among the 69 studies in Colorectal Neoplasms by Memorial Sloan Kettering Cancer Center, this one is the 3rd largest by planned enrollment of the 21 observational ones that give a count, is one of 4 that started in 2026, is one of 21 observational ones, reaches primary completion later than 15 of the 17 other live ones, and was the 67th registered.
6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →12 of the 69 studies in Colorectal Neoplasms by Memorial Sloan Kettering Cancer Center are open now, in 6 countries. Recruiting first, the newest first:
Memorial Sloan Kettering Cancer Center · Sites in United States, Ghana, South Africa and 1 more country
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States, Mexico
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States, Nigeria
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 25 · Phase 3 2
First in 1981; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 250 across 1,444 observational studies indexed under Colorectal Neoplasms.
Median enrollment 35 across the 35 interventional studies, 110 across the 21 observational. Of the 50 that completed or were terminated, 9 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
Memorial Sloan Kettering Cancer Center is the lead sponsor of 1,964 studies on the registry; 325 are open to participants now.
Of its 135 completed or terminated interventional studies of FDA-regulated products, 71 (53%) have results posted.
12 of the studies in Colorectal Neoplasms by Memorial Sloan Kettering Cancer Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06130280Memorial Sloan Kettering Cancer CenterA Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) Guided by Magnetic Resonance Imaging (MRI) in People With Liver Metastasis From Colorectal Cancer | 2026-11 |
| NCT00335816Memorial Sloan Kettering Cancer CenterRadiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal Cancer | 2026-12 |
| NCT04668872Memorial Sloan Kettering Cancer CenterBiopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation | 2026-12-07 |
| NCT03038568Memorial Sloan Kettering Cancer CenterAssessing How Normal Variations in CT Scanning Affects Its Interpretation | 2027-01-27 |
| NCT04812912Memorial Sloan Kettering Cancer CenterChanges in Reproductive and Sexual Health in People With Early Onset Colorectal Cancer | 2027-03-18 |
Add all 12 to your calendar (.ics) → With an account.
Among the 69 studies in Colorectal Neoplasms by Memorial Sloan Kettering Cancer Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to learn more about malignant colorectal polyps (early colorectal cancers removed during colonoscopy) and the risk that cancer remains, comes back, or spreads after the polyp is removed. The researchers also want to understand how patients and doctors make decisions about whether to have surgery or to be followed closely without surgery after a malignant polyp is removed.
This is an observational study. Participants will not receive any study treatment, and their care will be decided by them and their doctors as usual. The researchers will collect information from participants' medical records, including test results, imaging scans, lab work, and pathology reports, and may collect images from colonoscopy and copies of the pathology slides of the polyp. Participants will be asked to complete short questionnaires about how they view their risk and what influenced their treatment decision. The researchers will follow participants' health over time through their regular doctor visits; if no visit is scheduled, a member of the study team will contact participants by phone at 1, 3, and 5 years after they join the study.
The criteria were revised on the registry on Nov 20, 2026. See what changed
Adults with a single endoscopically resected malignant colorectal polyp (pT1 colorectal cancer) evaluated at Memorial Sloan Kettering Cancer Center. Patients seen in the Colorectal Surgery outpatient clinics at MSK Manhattan and MSK regional sites will be prospectively screened; eligible patients identified in other MSK clinics may also be invited to participate. Patients may enroll regardless of pathologic risk features and regardless of whether they choose surgery or nonoperative surveillance.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
patients who choose colorectal resection after endoscopic removal of a malignant polyp
Other: Questionnaires
patients who choose surveillance without surgery
Other: Questionnaires
risk-perception/decision-making questionnaire and validated risk-attitude scales, completed once during evaluation (both cohorts)
Risk of residual disease and/or recurrent disease
Residual disease is defined as cancer in the bowel wall or regional lymph nodes found at surgery performed after endoscopic resection (assessed in participants who undergo surgery). Recurrent disease is defined as local or distant reappearance of cancer during follow-up (assessed in all participants). Rates will be estimated using the Kaplan-Meier method with 95% confidence intervals.
Time frame: Up to 5 years
Disease-free survival
time from endoscopic removal of the malignant polyp to local recurrence, distant recurrence, or death
Time frame: Up to 5 years
Overall survival
time from endoscopic removal to death from any cause
Time frame: Up to 5 years
Local recurrence rate
reappearance of cancer at or near the site of the original polyp
Time frame: Up to 5 years
Distant recurrence rate
spread of cancer to sites distant from the original polyp
Time frame: Up to 5 years
Factors associated with patient treatment choice
association of risk perception, priorities and risk attitudes (study questionnaire, PRT, HRAS-6, DOSPERT-M) with choice of surgery vs surveillance
Time frame: at enrollment
Accuracy of surgeon risk assessment
Concordance between surgeons' estimated risk of residual or recurrent disease at diagnosis (before and after multidisciplinary discussion) and observed outcomes
Time frame: Up to 5 years
Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made following one year after publication and for up to 36 months later. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.
Started May 2026 (actual). Primary completion is estimated for May 2029, 36 months after the start.
Of 531 non-industry observational studies under Colorectal Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 132. This study's planned 36 months is below that.
Counting every sponsor, half of 648 studies reached it within 52 months; a quarter within 27 and three quarters within 104.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Memorial Sloan Kettering Cancer Center →